Multi-Layer ADHD Drug Composition with Delayed Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ADHD and other CNS stimulant-responsive conditions face challenges in maintaining effective drug concentration throughout the day, particularly in morning and afternoon when cognitive abilities are needed, due to the rapid release of medications leading to compliance issues and side effects.
Innovation Solution
Development of novel pharmaceutical compositions with a core comprising a CNS stimulant, a sustained release layer, and a delayed release layer, allowing for a controlled release of the drug over 4 to 12 hours, providing a therapeutic effect from waking to the active part of the day with a single evening dose, and adjustable lag time through formulation design.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If immediate release formulations are used for ADHD treatment, then the drug releases quickly achieving therapeutic effect, but compliance problems occur due to twice daily administration
Solution Approach 1:
The patent segments the drug release process into distinct phases using coated particles with multiple layers: an immediate release layer for rapid initial effect, a sustained release layer for extended therapeutic coverage, and a delayed release layer for afternoon/evening coverage. This segmentation allows a single daily dose to provide comprehensive coverage throughout the day, eliminating the need for twice-daily administration and improving patient compliance.
2Ease of operation
If long-acting formulations are developed to extend drug release to 8-14 hours, then compliance improves with single daily dose, but effective concentration is not maintained throughout the full day
Solution Approach 1:
The patent applies local quality by creating particles with spatially differentiated release characteristics. Each particle contains an immediate release layer (providing rapid initial concentration), a sustained release layer (maintaining steady concentration), and a delayed release layer (providing afternoon/evening boost). This local differentiation within each particle ensures that effective concentration is maintained throughout the entire day with a single dose, addressing both compliance and reliability requirements.
3Productivity
If rapid drug release is used to achieve quick therapeutic effect, then cognitive improvement is rapid, but side effects increase and compliance decreases
Solution Approach 1:
The patent implements periodic action through its multi-layer release system that delivers the drug in distinct phases: an initial rapid release phase (immediate release layer) for quick cognitive improvement, followed by a sustained moderate release phase (sustained release layer) that maintains therapeutic effect with reduced peak concentrations, and finally a delayed release phase (delayed release layer) for afternoon coverage. This periodic delivery pattern achieves rapid cognitive improvement while minimizing side effects associated with sustained high peak concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions ensure a sustained therapeutic effect throughout the day with reduced side effects by delaying and controlling the release of CNS stimulants, allowing patients to wake up with a minimal therapeutic dose already absorbed, maintaining concentration and reducing peak plasma concentration variability.
Implementation Method 1
The outer, pH dependent layer dissolves in the higher pH of the ileum or colon. As the sustained release layer then loses integrity the sustained release layer ruptures and releases the remaining drug in the core.
Data Source
AI summary
Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.